Tikun Olam-Cannbit Pharmaceuticals Ltd
TFSHF
Other OTC1.50
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
26.84
3Y
- -
77.03
5Y
- -
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Avinoam Sapir CPA
- Full Time Employees
- 102
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Hitad 2 Nof HaGalil Israel
- IPO Date
- Jul 27, 2020
- Website
- tikun-olam.org.il
- Similar Companies
- Business
- Tikun Olam-Cannbit Pharmaceuticals Ltd engages in the cultivation, production, marketing, storage, distribution, export, import, and sale of medical cannabis-based products. The company offers a broad portfolio of cannabis products tailored for medical use to treat and alleviate symptoms across numerous medical indications including cancer, PTSD, epilepsy, chronic pain, multiple sclerosis, Crohn's disease, and cerebral palsy. It also provides patient training, counseling, and care services, maintaining personalized treatment regimens with consistent active ingredient profiles. Tikun Olam-Cannbit operates an integrated ecosystem encompassing clinical research and trials, genetic R&D for unique strain development, cultivation and propagation farms, advanced production and laboratory facilities, technological R&D, a logistics center, dispensary operations, and direct home delivery services. The company serves primarily the Israeli market with expanding export operations and is recognized as a pioneer in medical cannabis. Founded in 2006 and headquartered in Nof HaGalil, Israel, Tikun Olam merged with Cannbit Pharmaceuticals Ltd in 2019, forming Israel’s leading medical cannabis supplier. Recent strategic developments include a collaboration with Canonic, part of the Evogene Group, combining Cannbit’s clinical cannabis expertise and extensive patient data with Canonic’s computational biology and cannabis breeding technologies to develop targeted cannabis strains and products with stable active compounds. The company has also secured EU-GMP certification for production and marketing, enabling expanded operations into the European pharmaceutical market. Latest initiatives focus on clinical research-driven, indication-specific cannabis products and innovative administration methods designed for global pharmaceutical partnerships and commercial distribution. Tikun Olam-Cannbit's leadership team includes Chairman and CEO Ronen Elad, steering growth through research, international expansion, and product innovation within the medical cannabis sector. The company trades on the Tel Aviv Stock Exchange under the ticker TKUN.